Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised to reshape drug development.
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
Biotech Limited Partners: learnings from investing in biotech venture capital funds
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
Enabling every cure for community matters: Our AI-powered journey
As we move through 2024, I’m thrilled with the extraordinary work our team is doing to change how we finance drug development: from funding next-generation therapies to helping others identify the highest potential cures in their development pipelines.
